Synthetic chemical diversity: solid phase synthesis of libraries of C2 symmetric inhibitors of HIV protease containing diamino diol and diamino alcohol cores.
Solid phase synthesis of non-oligomeric organic compounds has been pursued for high-efficiency generation of large numbers of structurally diverse compounds for drug screening. Known as chemical diversity libraries or combinatorial libraries (when the synthesis is carried out in a combinatorial fashion), these compounds can be used for de novo discovery of drug leads or for expedient structure--activity relationship (SAR) studies. To expand the scope of solid phase synthesis beyond the capability of the traditional method of solid phase synthesis for peptides, a strategy was developed for bi-directional solid phase synthesis starting with diamino alcohol or diamino diol core structures. The strategy relies on using bifunctional linkers to modify the core structures, simultaneously protecting the hydroxyl group or the diol moiety of the core and providing a carboxyl group for attachment of the modified cores to a solid support. The two NH2 groups of the modified cores attached to the solid support were then deprotected and reacted with a wide variety of amine-reactive reagents (carboxylic acids, sulfonyl chlorides, isocyanates, chloroformates, etc.) to extend the molecule in both directions. This strategy was successfully applied to automated parallel synthesis of a library of C2 symmetric inhibitors of HIV protease containing the known symmetry-based diamino diol and diamino alcohol core structures, thus enabling expedient access of large numbers of analogs in this series. A library of over 300 discrete compounds was synthesized using this methodology in order to identify potent (IC50 < 100 nM) HIV protease inhibitors with reduced size. This paper describes the technical aspects of this technology.
Wang
G T
GT
Pharmaceutical Product Division, Abbott Laboratories, Abbott Park, Illinois 60064, USA.
Li
S
S
Wideburg
N
N
Krafft
G A
GA
Kempf
D J
DJ
D000438:Alcohols / Q000737:chemistry / Q000494:pharmacology; D005240:Feasibility Studies; D017320:HIV Protease Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry; D006801:Humans; D008782:Methylurea Compounds / Q000737:chemistry; D011725:Pyridines / Q000737:chemistry; D013329:Structure-Activity Relationship; D014633:Valine / Q000031:analogs & derivatives
D000438:Alcohols; D017320:HIV Protease Inhibitors; D008782:Methylurea Compounds; D011725:Pyridines; C092970:A 80987; C079555:Abbott 77003; D014633:Valine